Revive Therapeutics (RVV) Stock Price, News & Analysis

Company Overview

Revive Therapeutics Ltd. develops and commercializes cannabinoid-based products in Canada. The company develops REV-002, a bucillamine that has completed Phase II-A clinical studies for the treatment of acute gout flares. Its product pipeline also includes REV-004, a bucillamine for the treatment of cystinurial. The company has a research and development supply and collaboration agreement with WeedMD Inc. Revive Therapeutics Ltd. was incorporated in 2012 and is headquartered in Vaughan, Canada.

Key Stats

• Today's Range: C$0.08 to C$0.09
• 50-Day Range: C$0.08 to C$0.08
• 52-Week Range: C$0.07 to C$0.25
• Volume: 212,852 shs
• Average Volume: 93,085 shs
• Market Capitalization: C$5.79 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Industry, Sector and Symbol

• Stock Exchange: CVE
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: CVE:RVV
• CIK: N/A
• Web: www.revivethera.com
• Phone: +1-905-6055535
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.14
• Quick Ratio: 6.03

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: C$0.03 per share
• Price / Cash Flow: 3.18
• Book Value: C$0.02 per share
• Price / Book: 4.21

Miscellaneous

• Outstanding Shares: 72,411,000
• Free Float: N/A
• Market Cap: C$5.79 million
• Optionable: Not Optionable
• Beta: N/A